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The Effect of Antihypertensive Dosing on
Hypertension in Children with Chronic Kidney Disease
Matta BA, Alon US, Srivastava T, Warady BA, Weidemann D
Division of Nephrology, Children’s Mercy Hospital Kansas City, Kansas City, MO

Background
• Hypertension (HTN) is a highly prevalent and major risk factor for
poor cardiovascular and renal outcomes in chronic kidney disease
(CKD).
• Previous research suggests that HTN is underdiagnosed and
undertreated in children with CKD (Hypertension 2018;71:1-7).
• To our knowledge no studies have investigated the effect of
antihypertensive dose on blood pressure control in this population.

Results
Logistic Regression Analysis
Model 1: Predictors of Uncontrolled Hypertension

Tables 2 and 3

Figure 1

Objective
• To determine the effect of antihypertensive dose on HTN status in
children with CKD.
• Hypothesis: Uncontrolled HTN is associated with lower
antihypertensive dose.

Model 2: Predictors of LVH

Figure 2

Figure 3

Methods
Study population: 255 participants studied in the Chronic Kidney
Disease in Children (CKiD) study at their third visit.
Inclusion criteria: Age 1-16 years with estimated GFR 30-90
mL/min/1.73m2, taking at least one antihypertensive medication,
successful 24h ABPM study.
Exclusion: White-coat hypertension (n=5).
Study variables:
• Cumulative Drug Dose Index (cDDI): We developed a new
quantitative tool, Drug Dose Index (DDI, Fig 1) which expresses
dose as a ratio between the current dose and the maximum
potential dose, accounting for age, weight and if indicated, renal
dose adjustments. cDDI is the sum DDI for all antihypertensive
agents taken by the subject.
• Primary outcome: HTN status classified into controlled HTN
(cHTN) or uncontrolled HTN (uHTN = masked HTN or ambulatory
HTN) based on 2017 AAP guidelines and 24h ABPM study.
• Secondary outcome: Left ventricular hypertrophy (LVH =
LVMI>38g/m2).
Statistical analysis:
Univariate analysis: t-test and ANOVA (continuous variables) and
chi-square test (categorical variables) used to compare cDDI
between the outcome groups (Fig 4): a) cHTN vs. uHTN, b) cHTN,
MH vs. AH, and c) LVH vs. no LVH.
Multivariate Logistic Regression Analysis:
• Two outcomes: Table 2) uHTN and Table 3) LVH.

Figure 4
a.
Table 1
Summary of Sociodemographic, clinical and
pharmacological factors

Discussion

*

b.

• No differences in cDDI between uHTN vs. cHTN, or LVH vs. no
LVH, but higher cDDI was associated with AH on univariate
analysis.
• Non-Caucasian race, absence of RAASi and diuretic agents, and
higher number of agents were associated with greater odds of
uHTN.
• Female gender, higher BMI z-score, lower eGFR, higher number
of agents and lower cDDI were associated with greater odds of
LVH.

Conclusions
c.

*Missing data: 5 patients with unknown CKD onset

• This was the first quantitative analysis of antihypertensive dose
expressed as a newly developed measure, cDDI, and its
relationship with hypertension status in children with CKD.
• Lower dose (cDDI) is not a significant predictor of uHTN,
however it may be associated with LVH.
• RAASi and diuretic use were associated with lower odds of
uHTN.
• Further research is needed to validate the use of cDDI and the
the roles of medication class and dose on blood pressure control
in children with CKD.

